Phenylalanine

Clinical Research as Care: Cut the Patient off Post Clinical Trial—A Lose-Lose in the End

May 12, 2019 | Blog, Orphan Drug, Phenylalanine, PKU, Price Watch, Rare Diseases

Deborah Cohen of the BBC reports that patients in the UK who contributed to orphan studies only to be cut from ongoing access once the study is completed. The patient receives care from the clinical trial only to be cut once the trial is over and the drug approved....

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

159 WEST BROADWAY SUITE 200
SALT LAKE CITY, UT 84101

Clinical Research as Care: Cut the Patient off Post Clinical Trial—A Lose-Lose in the End

Pin It on Pinterest